Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy-Reference-Cited by-同舟云学术

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy

Published:2024-08-23 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Taha Zaid^ORCID,Crupi Mathieu Joseph François^ORCID,Alluqmani Nouf,MacKenzie Duncan,Vallati Sydney,Whelan Jack Timothy,Fareez Faiha,Alwithenani Akram,Petryk Julia,Chen Andrew,Spinelli Marcus Mathew,Ng Kristy,Sobh Judy,de Souza Christiano Tanese,Bharadwa Priya Rose,Lee Timothy Kit Hin,Thomas Dylan Anthony,Huang Ben Zhen,Kassas Omar,Poutou Joanna,Gilchrist Victoria Heather,Boulton Stephen^ORCID,Thomson Max,Marius Ricardo,Hooshyar Mohsen,McComb Scott,Arulanandam Rozanne^ORCID,Ilkow Carolina Solange,Bell John Cameron^ORCID,Diallo Jean-Simon^ORCID

Funder

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre

Terry Fox Research Institute

Mitacs

Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada

Canadian Cancer Society Research Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-51498-0.pdf

Reference56 articles.

1. Finck, A., Gill, S. I. & June, C. H. Cancer immunotherapy comes of age and looks for maturity. Nat. Commun. 11, https://doi.org/10.1038/s41467-020-17140-5 (2020).

2. Arulanandam, R. et al. The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. Commun. Biol. 3, 254 (2020).

3. von Minckwitz, G. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 380, 617–628 (2019).

4. Cortés, J. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N. Engl. J. Med. 386, 1143–1154 (2022).

5. Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101–126, (2023).